Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion

Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion

Item
http://www.wikidata.org/entity/Q28296706
Bispecific antibodies for cancer therapy: the light at the end of the tunnel?Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisitedNCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantatioRelapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome.Long-term outcome after autologous or allogeneic stem cell transplantation in patients with recurrent follicular lymphoma.Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-drInvestigational immunotherapeutics for B-cell malignancies.Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation.New antibody drug treatments for lymphoma.Cancer therapy with trifunctional antibodies: linking innate and adaptive immunity.Multi-specific antibodies for cancer immunotherapy.Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer.Hematopoietic stem cell transplantation and cellular therapy.Redirecting T cells to hematological malignancies with bispecific antibodies.Immunotherapy with the trifunctional anti-CD20 × anti-CD3 antibody FBTA05 in a patient with relapsed t(8;14)-positive post-transplant lymphoproliferative disease.Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies.Emerging classes of armed antibody therapeutics against cancer
P2860

Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion

Item
http://www.wikidata.org/entity/Q28296706
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Immunotherapy of recurrent B-c ...... and donor lymphocyte infusion
@ast
Immunotherapy of recurrent B-c ...... and donor lymphocyte infusion
@en
Immunotherapy of recurrent B-c ...... and donor lymphocyte infusion
@nl
type
label
Immunotherapy of recurrent B-c ...... and donor lymphocyte infusion
@ast
Immunotherapy of recurrent B-c ...... and donor lymphocyte infusion
@en
Immunotherapy of recurrent B-c ...... and donor lymphocyte infusion
@nl
prefLabel
Immunotherapy of recurrent B-c ...... and donor lymphocyte infusion
@ast
Immunotherapy of recurrent B-c ...... and donor lymphocyte infusion
@en
Immunotherapy of recurrent B-c ...... and donor lymphocyte infusion
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P6179
P698
P921
P356
P1433
P1476
Immunotherapy of recurrent B-c ...... and donor lymphocyte infusion
@en
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P6179
P698
P921